ADARx Pharmaceuticals, Inc. ADRX
14.00 USD -0.20 (-1.41%)
Regular-session close
14.00 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
13.08 Day range 15.21
12.50 52-week range 23.21
- YTD
- -27.65%
- 1 year
- -27.65%
News
seekingalpha.com ADARx Pharmaceuticals, Inc. (ADRX) Presents at UBS Global Biopharma Conference 2026 Transcript ADARx Pharmaceuticals, Inc. ( ADRX ) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM EST Company Participants Li Zhen - Co-Founder, President, CEO & Director Conference Call…benzinga.com Adarx Pharmaceuticals Q3 EPS $(1.74) Misses $(0.31) Estimate, Sales $2.200M Miss $2.583M Estimate Adarx Pharmaceuticals (NASDAQ:ADRX) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(0.31) by 461.29 percent. This is a 5.95 percent increase over…
globenewswire.com ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates – Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 – –…benzinga.com JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38 JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
benzinga.com This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated bullish coverage on ADRX ($32), NWSA ($35), MOD ($275), SITM ($750) and QSR ($85), with Overweight, Outperform or Buy ratings.benzinga.com UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35 UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.
benzinga.com Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32 Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.
